MyoKardia, Inc. Income Statement | Understand Stock

Login

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Operations and Comprehensive Loss

In millions of USD; shares in millions, except per-share amounts

	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017	FY2016 12 months to Dec 31, 2016	FY2015 12 months to Dec 31, 2015
Collaboration and license revenue
Operating expenses:
Repurchase of royalty rights
Research and development
Selling, general and administrative
Total operating expenses
Loss from operations
Interest and other income, net
Change in fair value of redeemable convertible preferred stock call option liability
Net loss
Other comprehensive income (loss)
Comprehensive loss
Cumulative dividend relating to redeemable convertible preferred stock
Accretion of redeemable convertible preferred stock to redemption value
Net loss attributable to common stockholders
Net loss per share, basic and diluted
Weighted average number of shares used to compute net loss per share, basic and diluted

Loading...

Comments